EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of ASXL1 Gene Alterations on Myelodysplastic Syndrome With Isolated 20q Deletion

Yanan Chang, Linlin Liu, Chenghua Cui, Jiange He, Chengwen Li, Yujiao Jia, Ruixue Zhang, Wanyun Wu, Ji Zhou, Jigang Xiao, Zefeng Xu, Tiejun Qin und 3 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.70747 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Yanan Chang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hematologic Pathology Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College…. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Repressor Proteins, Chromosome Deletion. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Isolated 20q deletion [del(20q)] is a recurrent favorable abnormality in myelodysplastic syndrome (MDS) and may cause deletion of the ASXL1 gene. Meanwhile, ASXL1 mutations are also common in individuals with MDS. This study aimed to describe the biological and clinical implications of ASXL1 mutations and deletion in newly diagnosed MDS patients with isolated del(20q).

Methods

Gene mutation and copy number alterations in 178 newly diagnosed MDS patients with isolated del(20q) were analyzed using DNA next generation sequencing.

Results

Twenty‐five (14%) of 178 patients were found to have ASXL1 mutations, which exhibited lower absolute neutrophil counts (ANC) ( p = 0.006), a higher percentage of bone marrow blasts ( p = 0.001), more mutant genes ( p < 0.001), higher IPSS‐R ( p = 0.038) and IPSS‐M ( p = 0.001) risk groups. Furthermore, ASXL1 mutations were preferentially associated with mutations in U2AF1 , and most ASXL1 mutations (68%) were observed as subclonal lesions. ASXL1 frameshift mutations were associated with a worse prognosis in MDS patients with low blasts (MDS‐LB) ( p = 0.043), but not in those with increased blasts (MDS‐IB). Twenty‐two (26.8%) of 82 patients were found to have ASXL1 deletion, which exhibited a lower IPSS‐M risk group, lower platelet counts, higher ANC levels, and higher hemoglobin levels compared to ASXL1 patients only‐mut and ASXL1 wt patients. Two (2.4%) of the 82 patients exhibited biallelic ASXL1 inactivation ( ASXL1 mut&del ).

Conclusions

ASXL1 mutations are one of the late genetic events in MDS patients with isolated 20q deletion, and different types of ASXL1 gene alterations have distinct clinical and biological characteristics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesRepressor ProteinsChromosome DeletionHumansMaleFemaleMiddle AgedAgedAdultPrognosisAged, 80 and overMutationDNA Copy Number VariationsHigh-Throughput Nucleotide Sequencing

Stichwörter der Autor:innen

ASXL120q deletioncopy number variantmutationmyelodysplastic syndrome

Substanzen

ASXL1 protein, humanRepressor Proteins

Autor:innen und Institutionen

  • Hematologic Pathology Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • Hand and Foot Microsurgery, The Second Hospital of Tianjin Medical University, Tianjin, China.
  • Peking University People's Hospital, Beijing, China.
  • MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.

ORCID-Profile: Zhijian Xiao

Förderung

  • Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
  • National Natural Science Foundation of China

Zitieren

APA

Chang, Y., Liu, L., Cui, C., He, J., Li, C., Jia, Y., Zhang, R., Wu, W., Zhou, J., Xiao, J., Xu, Z., Qin, T., Sun, Q., Wang, H., & Xiao, Z. (2025). Impact of ASXL1 Gene Alterations on Myelodysplastic Syndrome With Isolated 20q Deletion. Cancer Medicine. https://doi.org/10.1002/cam4.70747

Vancouver

Chang Y, Liu L, Cui C, He J, Li C, Jia Y, et al. Impact of ASXL1 Gene Alterations on Myelodysplastic Syndrome With Isolated 20q Deletion. Cancer Medicine. 2025. doi:10.1002/cam4.70747

BibTeX
@article{Chang2025,
  author = {Chang, Yanan and Liu, Linlin and Cui, Chenghua and He, Jiange and Li, Chengwen and Jia, Yujiao and Zhang, Ruixue and Wu, Wanyun and Zhou, Ji and Xiao, Jigang and Xu, Zefeng and Qin, Tiejun and Sun, Qi and Wang, Huijun and Xiao, Zhijian},
  title = {Impact of ASXL1 Gene Alterations on Myelodysplastic Syndrome With Isolated 20q Deletion},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70747}
}
Kostenlos starten →